Jung-Chen Su Selected Research

obatoclax

2/2015	Copper-obatoclax derivative complexes mediate DNA cleavage and exhibit anti-cancer effects in hepatocellular carcinoma.
7/2014	RFX1-dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells.
7/2014	Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
7/2014	SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
8/2012	A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jung-Chen Su Research Topics

Disease

21	Neoplasms (Cancer) 01/2021 - 11/2008
7	Breast Neoplasms (Breast Cancer) 11/2017 - 02/2010
6	Hepatocellular Carcinoma (Hepatoma) 02/2015 - 08/2012
4	Triple Negative Breast Neoplasms 11/2017 - 01/2016
2	Colorectal Neoplasms (Colorectal Cancer) 01/2018 - 01/2016
2	Leukemia 07/2014 - 11/2008
2	Squamous Cell Carcinoma of Head and Neck 06/2010 - 10/2009
2	Adenocarcinoma of Lung 01/2010 - 09/2009
1	Hypoxia (Hypoxemia) 01/2022
1	Melanoma (Melanoma, Malignant) 07/2017
1	Neoplasm Metastasis (Metastasis) 01/2016
1	Carcinogenesis 01/2016
1	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2016
1	Liver Neoplasms (Liver Cancer) 07/2014
1	Carcinoma (Carcinomatosis) 07/2014
1	Lymphoma (Lymphomas) 07/2014
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2009

Drug/Important Bio-Agent (IBA)

5	Pharmaceutical PreparationsIBA 01/2021 - 01/2013
5	SC-2001IBA 07/2017 - 08/2012
5	obatoclaxIBA 02/2015 - 08/2012
4	Proteins (Proteins, Gene)FDA Link 01/2022 - 01/2013
4	Sorafenib (BAY 43-9006)FDA Link 11/2017 - 01/2013
3	regorafenibIBA 01/2018 - 11/2014
3	N-formyl-13-dihydrocarminomycin (NFD)IBA 06/2010 - 01/2010
3	furanIBA 06/2010 - 01/2010
2	Docetaxel (Taxotere)FDA Link 09/2017 - 01/2017
2	Phosphotransferases (Kinase)IBA 01/2017 - 01/2016
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016 - 11/2008
2	Cyclin D1IBA 01/2013 - 11/2008
2	ErbB Receptors (EGF Receptor)IBA 06/2010 - 10/2009
2	DiaminesIBA 09/2009 - 11/2008
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2022
1	UbiquitinIBA 01/2022
1	napabucasinIBA 01/2018
1	nintedanibIBA 11/2017
1	Tyrosine Kinase InhibitorsIBA 11/2017
1	ABT-737IBA 07/2017
1	Apoptosis Regulatory ProteinsIBA 07/2017
1	Protein Tyrosine PhosphatasesIBA 06/2017
1	SH2 Domain-Containing Protein Tyrosine PhosphatasesIBA 06/2017
1	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 06/2017
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2016
1	indoleIBA 02/2015
1	ProdigiosinIBA 02/2015
1	PyrrolesIBA 02/2015
1	CopperIBA 02/2015
1	Transcription Factors (Transcription Factor)IBA 12/2014
1	Biological ProductsIBA 12/2014
1	Phosphoprotein Phosphatases (Phosphatases, Protein)IBA 09/2014
1	Estrogen ReceptorsIBA 09/2014
1	Tamoxifen FDA LinkGeneric 09/2014
1	SurvivinIBA 01/2013
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2012
1	QuinazolinesIBA 10/2012
1	Oncogene Proteins (Oncogene Protein)IBA 10/2012
1	pyrimidineIBA 10/2012
1	lawsoneIBA 06/2010
1	chloroacetaldehydeIBA 06/2010
1	Epidermal Growth Factor (EGF)IBA 06/2010
1	Cobra Cardiotoxin ProteinsIBA 06/2010
1	VenomsIBA 10/2009
1	Amino Acids FDA Link 10/2009
1	CardiotoxinsIBA 10/2009
1	Peptides (Polypeptides)IBA 10/2009
1	Mitogen-Activated Protein KinasesIBA 09/2009
1	Mitogen-Activated Protein Kinase 3IBA 11/2008
1	Antineoplastic Agents (Antineoplastics)IBA 11/2008

Therapy/Procedure

4	Therapeutics 09/2017 - 12/2014